Abstract
A patient with essential hypertension had a prolonged period of uncontrollable high blood pressure during therapy with the nonspecific beta-blocker nadolol. A subsequent challenge with the beta1-blocker atenolol caused a pressor response associated with diminished catecholamine release, impaired catecholamine clearance, loss of baroreflex response, and bradycardia. Beta-blocking drugs can lead to hypertension by causing fluid retention, reversal of catecholamine vasodilatation, or a direct pressor effect.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 81-88 |
| Number of pages | 8 |
| Journal | Clinical Therapeutics |
| Volume | 7 |
| Issue number | 1 |
| State | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Pressor response to beta-blocking drugs. / Ziegler, M. G.; Woodson, L. C.
In: Clinical Therapeutics, Vol. 7, No. 1, 1984, p. 81-88.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pressor response to beta-blocking drugs
AU - Ziegler, M. G.
AU - Woodson, L. C.
PY - 1984
Y1 - 1984
N2 - A patient with essential hypertension had a prolonged period of uncontrollable high blood pressure during therapy with the nonspecific beta-blocker nadolol. A subsequent challenge with the beta1-blocker atenolol caused a pressor response associated with diminished catecholamine release, impaired catecholamine clearance, loss of baroreflex response, and bradycardia. Beta-blocking drugs can lead to hypertension by causing fluid retention, reversal of catecholamine vasodilatation, or a direct pressor effect.
AB - A patient with essential hypertension had a prolonged period of uncontrollable high blood pressure during therapy with the nonspecific beta-blocker nadolol. A subsequent challenge with the beta1-blocker atenolol caused a pressor response associated with diminished catecholamine release, impaired catecholamine clearance, loss of baroreflex response, and bradycardia. Beta-blocking drugs can lead to hypertension by causing fluid retention, reversal of catecholamine vasodilatation, or a direct pressor effect.
UR - http://www.scopus.com/inward/record.url?scp=0021710738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021710738&partnerID=8YFLogxK
M3 - Article
C2 - 6151422
AN - SCOPUS:0021710738
VL - 7
SP - 81
EP - 88
JO - Clinical Therapeutics
JF - Clinical Therapeutics
SN - 0149-2918
IS - 1
ER -